Healthcare Copywriting

In high-stakes sectors like BioTech and Life Sciences, creative copy can be a liability if it isn’t anchored in clinical accuracy and regulation. Yet marketing principles still apply! Establish pain points, hook from SEO, point audience towards a solution, reassure via targeted objection handling. 

0

In B2B Copy

If you’re talking to experts in a field, regulators, scientists, doctors or other HCPs, trying to convince them to invest time, money or approval in a drug, therapeutic approach, or institution, then you need to stop selling the promise and start proving the mechanism. These audiences don’t buy ‘vision’, they buy into rigour, reproducibility, and risk mitigation. If your narrative leads with adjectives instead of endpoints, you’ve already lost the room.

0

You also need to speak multiple languages: 

• Scientists want to know mechanism and method. They care about how and the why. Is the biological rationale sound? Are the assays validated? Is the data reproducible under rigorous scrutiny, or is it an artifact of a flawed model? 
• Doctors want to know the safety profile, reproducibility, and risk-benefit ratio. They care about compliance, standard operating procedures, and population-level risk. Are your primary endpoints clinically relevant? Is your manufacturing process consistent and scalable? Have you accounted for toxicities and vulnerable sub-populations? 
• Investors and corporates want to know the market viability, defensibility, and path to liquidity. They care about the return on capital and the timeline to value inflection points. How strong is the IP moat? What does the reimbursement landscape look like? Is the leadership team capable of executing clinical trials on budget? 

0

In D2C Copy

Now suddenly you’re talking to consumers. Maybe it’s cosmetics, maybe it’s a hospice or a sports or wellbeing related charity, maybe it actually is pharmaceuticals in a country where it’s legal to market them to the public, but you still don’t get to ignore the FDA, or any of the appropriate regulatory frameworks. To the contrary, your responsibility as a marketer actually increases! 

p

• A skincare brand sells an anti-aging cream, but the moment the copy promises to “repair cellular DNA,” “treat chronic inflammation,” or “reverse sun damage,” regulators like the FDA or FTC classify the product as an unapproved new drug. Consumers interpret these statements as clinical facts, triggering strict enforcement, warning letters, and product recalls.
• Marketing a prescription drugs directly to patients (e.g. in the US or New Zealand), means audiences that lack medical training to contextualise side effects. Consumers are inherently vulnerable to emotional appeals, so frameworks like the OPDP enforce strict rules, requiring risk disclosures and contraindications be presented.
• A hospice, cancer charity, or wellness foundation appealing to the public for donations or participation cannot make emotional, overstated efficacy claims about alternative therapies or patient outcomes either. Regulators and advertising standards authorities strictly monitor these claims to protect the emotionally vulnerable from exploitation.